Stentys Sirolimus-Eluting Stent Confirms Best-in-Class Performance At 3 Years

PRINCETON, N.J. &PARIS--(BUSINESS WIRE)--STENTYS (Paris:STNT) (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces that three-year follow-up imaging data from the STENTYS arm of the APPOSITION IV clinical study confirms the long-term performance of the sirolimus-eluting Self-Apposing stent. The data will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco, CA.

Help employers find you! Check out all the jobs and post your resume.